BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol. 2013;31:1267-1270. [PMID: 23460708 DOI: 10.1200/jco.2012.46.9403] [Cited by in Crossref: 168] [Cited by in F6Publishing: 86] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Fang S, Han J, Zhang M, Wang LE, Wei Q, Amos CI, Lee JE. Joint effect of multiple common SNPs predicts melanoma susceptibility. PLoS One 2013;8:e85642. [PMID: 24392023 DOI: 10.1371/journal.pone.0085642] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
2 Powers JM, Ebrahimzadeh JE, Katona BW. Genetic testing for hereditary gastrointestinal cancer syndromes: Interpreting results in today's practice. Curr Treat Options Gastroenterol 2019;17:636-49. [PMID: 31761969 DOI: 10.1007/s11938-019-00253-2] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Stadler ZK, Schrader KA, Vijai J, Robson ME, Offit K. Cancer genomics and inherited risk. J Clin Oncol 2014;32:687-98. [PMID: 24449244 DOI: 10.1200/JCO.2013.49.7271] [Cited by in Crossref: 88] [Cited by in F6Publishing: 45] [Article Influence: 12.6] [Reference Citation Analysis]
4 Slade I, Riddell D, Turnbull C, Hanson H, Rahman N; MCG programme. Development of cancer genetic services in the UK: A national consultation. Genome Med 2015;7:18. [PMID: 25722743 DOI: 10.1186/s13073-015-0128-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
5 Moore DA, Kushnir M, Mak G, Winter H, Curiel T, Voskoboynik M, Moschetta M, Rozumna-Martynyuk N, Balbi K, Bennett P, Forster M, Kulkarni A, Haynes D, Swanton C, Arkenau HT. Prospective analysis of 895 patients on a UK Genomics Review Board. ESMO Open 2019;4:e000469. [PMID: 31245058 DOI: 10.1136/esmoopen-2018-000469] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
6 Martinez KA, Kurian AW, Hawley ST, Jagsi R. How can we best respect patient autonomy in breast cancer treatment decisions? Breast Cancer Manag 2015;4:53-64. [PMID: 25733982 DOI: 10.2217/bmt.14.47] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
7 Nielsen SM, Eccles DM, Romero IL, Al-Mulla F, Balmaña J, Biancolella M, Bslok R, Caligo MA, Calvello M, Capone GL, Cavalli P, Chan TLC, Claes KBM, Cortesi L, Couch FJ, de la Hoya M, De Toffol S, Diez O, Domchek SM, Eeles R, Efremidis A, Fostira F, Goldgar D, Hadjisavvas A, Hansen TVO, Hirasawa A, Houdayer C, Kleiblova P, Krieger S, Lázaro C, Loizidou M, Manoukian S, Mensenkamp AR, Moghadasi S, Monteiro AN, Mori L, Morrow A, Naldi N, Nielsen HR, Olopade OI, Pachter NS, Palmero EI, Pedersen IS, Piane M, Puzzo M, Robson M, Rossing M, Sini MC, Solano A, Soukupova J, Tedaldi G, Teixeira M, Thomassen M, Tibiletti MG, Toland A, Törngren T, Vaccari E, Varesco L, Vega A, Wallis Y, Wappenschmidt B, Weitzel J, Spurdle AB, De Nicolo A, Gómez-García EB. Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. JCO Precis Oncol 2018;2. [PMID: 31517176 DOI: 10.1200/PO.18.00091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
8 Heitzer E, Lax S, Lafer I, Müller SM, Pristauz G, Ulz P, Jahn S, Högenauer C, Petru E, Speicher MR, Geigl JB. Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma. BMC Med Genet 2013;14:129. [PMID: 24373500 DOI: 10.1186/1471-2350-14-129] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
9 Yang L, Wang G, Zhao X, Ye S, Shen P, Wang W, Zheng S. A Novel WRN Frameshift Mutation Identified by Multiplex Genetic Testing in a Family with Multiple Cases of Cancer. PLoS One 2015;10:e0133020. [PMID: 26241669 DOI: 10.1371/journal.pone.0133020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
10 Schmidlen T, Sturm AC, Hovick S, Scheinfeldt L, Scott Roberts J, Morr L, McElroy J, Toland AE, Christman M, O'Daniel JM, Gordon ES, Bernhardt BA, Ormond KE, Sweet K. Operationalizing the Reciprocal Engagement Model of Genetic Counseling Practice: a Framework for the Scalable Delivery of Genomic Counseling and Testing. J Genet Couns 2018;27:1111-29. [PMID: 29460110 DOI: 10.1007/s10897-018-0230-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
11 Brédart A, Kop JL, Dick J, Cano A, De Pauw A, Anota A, Brunet J, Devilee P, Stoppa-Lyonnet D, Schmutzler R, Dolbeault S. Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study. BMJ Open 2019;9:e029926. [PMID: 31551380 DOI: 10.1136/bmjopen-2019-029926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bradbury AR, Patrick-Miller L, Domchek S. Multiplex genetic testing: reconsidering utility and informed consent in the era of next-generation sequencing. Genet Med 2015;17:97-8. [PMID: 25032987 DOI: 10.1038/gim.2014.85] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
13 Bradbury AR, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long JM, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS. Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. J Natl Cancer Inst 2018;110:985-93. [PMID: 29490071 DOI: 10.1093/jnci/djy015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
14 Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, Offit K, Robson ME. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 2016;13:581-8. [PMID: 27296296 DOI: 10.1038/nrclinonc.2016.90] [Cited by in Crossref: 187] [Cited by in F6Publishing: 128] [Article Influence: 37.4] [Reference Citation Analysis]
15 Bradbury AR, Patrick-Miller L, Long J, Powers J, Stopfer J, Forman A, Rybak C, Mattie K, Brandt A, Chambers R, Chung WK, Churpek J, Daly MB, Digiovanni L, Farengo-Clark D, Fetzer D, Ganschow P, Grana G, Gulden C, Hall M, Kohler L, Maxwell K, Merrill S, Montgomery S, Mueller R, Nielsen S, Olopade O, Rainey K, Seelaus C, Nathanson KL, Domchek SM. Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genet Med 2015;17:485-92. [PMID: 25297947 DOI: 10.1038/gim.2014.134] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
16 Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O'Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World J Gastrointest Oncol 2019;11:102-16. [PMID: 30788038 DOI: 10.4251/wjgo.v11.i2.102] [Reference Citation Analysis]
17 Vicuña B, Delaney HD, Flores KG, Ballinger L, Royce M, Dayao Z, Pal T, Kinney AY. Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families. J Community Genet 2018;9:81-92. [PMID: 28971318 DOI: 10.1007/s12687-017-0322-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Cadoo KA, Mandelker DL, Mukherjee S, Stewart C, DeLair D, Ravichandran V, Srinivasan P, Hurley D, Kemel Y, Arnold AG, Sheehan M, Pradhan N, Joseph V, Chi DS, Gardner GJ, Jewell EL, Leitao MM Jr, Roche KL, Mueller JJ, Sonoda Y, Zivanovic O, Walsh M, Carlo MI, Berger MF, Hyman D, Zhang L, Robson ME, Offit K, Aghajanian C, Rustum NRA, Stadler Z. Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer. JCO Precis Oncol 2019;3. [PMID: 32775946 DOI: 10.1200/po.18.00338] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Bunnell AE, Garby CA, Pearson EJ, Walker SA, Panos LE, Blum JL. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program. J Genet Couns 2017;26:105-12. [PMID: 27276934 DOI: 10.1007/s10897-016-9985-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
20 Medendorp NM, Hillen MA, Murugesu L, Aalfs CM, Stiggelbout AM, Smets EMA. Uncertainty related to multigene panel testing for cancer: a qualitative study on counsellors' and counselees' views. J Community Genet 2019;10:303-12. [PMID: 30430454 DOI: 10.1007/s12687-018-0393-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
21 Hamilton JG, Robson ME. Psychosocial Effects of Multigene Panel Testing in the Context of Cancer Genomics. Hastings Cent Rep 2019;49 Suppl 1:S44-52. [PMID: 31268573 DOI: 10.1002/hast.1016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
22 Catenacci DV, Amico AL, Nielsen SM, Geynisman DM, Rambo B, Carey GB, Gulden C, Fackenthal J, Marsh RD, Kindler HL, Olopade OI. Tumor genome analysis includes germline genome: are we ready for surprises? Int J Cancer 2015;136:1559-67. [PMID: 25123297 DOI: 10.1002/ijc.29128] [Cited by in Crossref: 59] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
23 Kaphingst KA, Kohlmann W, Chambers RL, Goodman MS, Bradshaw R, Chan PA, Chavez-Yenter D, Colonna SV, Espinel WF, Everett JN, Gammon A, Goldberg ER, Gonzalez J, Hagerty KJ, Hess R, Kehoe K, Kessler C, Kimball KE, Loomis S, Martinez TR, Monahan R, Schiffman JD, Temares D, Tobik K, Wetter DW, Mann DM, Kawamoto K, Del Fiol G, Buys SS, Ginsburg O; BRIDGE research team. Comparing models of delivery for cancer genetics services among patients receiving primary care who meet criteria for genetic evaluation in two healthcare systems: BRIDGE randomized controlled trial. BMC Health Serv Res 2021;21:542. [PMID: 34078380 DOI: 10.1186/s12913-021-06489-y] [Reference Citation Analysis]
24 Offit K. The future of clinical cancer genomics. Semin Oncol 2016;43:615-22. [PMID: 27899195 DOI: 10.1053/j.seminoncol.2016.10.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
25 Hiraki S, Rinella ES, Schnabel F, Oratz R, Ostrer H. Cancer risk assessment using genetic panel testing: considerations for clinical application. J Genet Couns 2014;23:604-17. [PMID: 24599651 DOI: 10.1007/s10897-014-9695-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
26 Bradbury AR, Patrick-Miller LJ, Egleston BL, DiGiovanni L, Brower J, Harris D, Stevens EM, Maxwell KN, Kulkarni A, Chavez T, Brandt A, Long JM, Powers J, Stopfer JE, Nathanson KL, Domchek SM. Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. Genet Med 2016;18:25-33. [PMID: 25834950 DOI: 10.1038/gim.2015.19] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 7.5] [Reference Citation Analysis]
27 LaDuca H, Stuenkel AJ, Dolinsky JS, Keiles S, Tandy S, Pesaran T, Chen E, Gau CL, Palmaer E, Shoaepour K. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med. 2014;16:830-837. [PMID: 24763289 DOI: 10.1038/gim.2014.40] [Cited by in Crossref: 217] [Cited by in F6Publishing: 177] [Article Influence: 31.0] [Reference Citation Analysis]
28 Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, Li Y, Hawley ST, Morrow M, Jagsi R, Katz SJ. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. JAMA Oncol 2018;4:1066-72. [PMID: 29801090 DOI: 10.1001/jamaoncol.2018.0644] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 36.5] [Reference Citation Analysis]
29 Sun S, Yang F, Tan G, Costanzo M, Oughtred R, Hirschman J, Theesfeld CL, Bansal P, Sahni N, Yi S, Yu A, Tyagi T, Tie C, Hill DE, Vidal M, Andrews BJ, Boone C, Dolinski K, Roth FP. An extended set of yeast-based functional assays accurately identifies human disease mutations. Genome Res 2016;26:670-80. [PMID: 26975778 DOI: 10.1101/gr.192526.115] [Cited by in Crossref: 61] [Cited by in F6Publishing: 45] [Article Influence: 12.2] [Reference Citation Analysis]
30 Yurgelun MB, Masciari S, Joshi VA, Mercado RC, Lindor NM, Gallinger S, Hopper JL, Jenkins MA, Buchanan DD, Newcomb PA, Potter JD, Haile RW, Kucherlapati R, Syngal S;  Colon Cancer Family Registry. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry. JAMA Oncol. 2015;1:214-221. [PMID: 26086041 DOI: 10.1001/jamaoncol.2015.0197] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 11.4] [Reference Citation Analysis]
31 Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 2014;343:1466-70. [PMID: 24675953 DOI: 10.1126/science.1251827] [Cited by in Crossref: 214] [Cited by in F6Publishing: 166] [Article Influence: 30.6] [Reference Citation Analysis]
32 Foley SB, Rios JJ, Mgbemena VE, Robinson LS, Hampel HL, Toland AE, Durham L, Ross TS. Use of Whole Genome Sequencing for Diagnosis and Discovery in the Cancer Genetics Clinic. EBioMedicine 2015;2:74-81. [PMID: 26023681 DOI: 10.1016/j.ebiom.2014.12.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
33 Radford C, Prince A, Lewis K, Pal T. Factors which impact the delivery of genetic risk assessment services focused on inherited cancer genomics: expanding the role and reach of certified genetics professionals. J Genet Couns 2014;23:522-30. [PMID: 24306140 DOI: 10.1007/s10897-013-9668-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
34 Rainville IR, Rana HQ. Next-generation sequencing for inherited breast cancer risk: counseling through the complexity. Curr Oncol Rep. 2014;16:371. [PMID: 24488544 DOI: 10.1007/s11912-013-0371-z] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
35 Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, McLeod MC, Jagsi R, Katz SJ. Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. J Clin Oncol 2017;35:2232-9. [PMID: 28402748 DOI: 10.1200/JCO.2016.71.6480] [Cited by in Crossref: 138] [Cited by in F6Publishing: 56] [Article Influence: 34.5] [Reference Citation Analysis]
36 Blazer KR, Nehoray B, Solomon I, Niell-Swiller M, Culver JO, Uman GC, Weitzel JN. Next-Generation Testing for Cancer Risk: Perceptions, Experiences, and Needs Among Early Adopters in Community Healthcare Settings. Genet Test Mol Biomarkers 2015;19:657-65. [PMID: 26539620 DOI: 10.1089/gtmb.2015.0061] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
37 Lundy MG, Forman A, Valverde K, Kessler L. An investigation of genetic counselors' testing recommendations: pedigree analysis and the use of multiplex breast cancer panel testing. J Genet Couns 2014;23:618-32. [PMID: 24569857 DOI: 10.1007/s10897-014-9692-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
38 Culver JO, Ricker CN, Bonner J, Kidd J, Sturgeon D, Hodan R, Kingham K, Lowstuter K, Chun NM, Lebensohn AP, Rowe-Teeter C, Levonian P, Partynski K, Lara-Otero K, Hong C, Morales Pichardo J, Mills MA, Brown K, Lerman C, Ladabaum U, McDonnell KJ, Ford JM, Gruber SB, Kurian AW, Idos GE. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. Cancer 2021;127:1275-85. [PMID: 33320347 DOI: 10.1002/cncr.33357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Spurdle AB, Bowman MA, Shamsani J, Kirk J. Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing. Mod Pathol 2017;30:1048-68. [PMID: 28452373 DOI: 10.1038/modpathol.2017.20] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
40 Silva-Smith R, Sussman DA. Co-occurrence of Lynch syndrome and juvenile polyposis syndrome confirmed by multigene panel testing. Fam Cancer 2018;17:87-90. [PMID: 28600700 DOI: 10.1007/s10689-017-0012-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
41 Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, Boolbol SK, Taylor WA. Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. Ann Surg Oncol 2019;26:3025-31. [PMID: 31342359 DOI: 10.1245/s10434-019-07549-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 38] [Article Influence: 31.0] [Reference Citation Analysis]
42 Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips KA. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol 2015;33:900-2. [PMID: 26348951 DOI: 10.1038/nbt.3322] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
43 Biller LH, Syngal S, Yurgelun MB. Recent advances in Lynch syndrome. Fam Cancer 2019;18:211-9. [PMID: 30627969 DOI: 10.1007/s10689-018-00117-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 11.5] [Reference Citation Analysis]
44 Slaught C, Berry EG, Bacik L, Skalet AH, Anadiotis G, Tuohy T, Leachman SA. Clinical challenges in interpreting multiple pathogenic mutations in single patients. Hered Cancer Clin Pract 2021;19:15. [PMID: 33541411 DOI: 10.1186/s13053-021-00172-3] [Reference Citation Analysis]
45 Underhill ML, Germansky KA, Yurgelun MB. Advances in Hereditary Colorectal and Pancreatic Cancers. Clin Ther 2016;38:1600-21. [PMID: 27045993 DOI: 10.1016/j.clinthera.2016.03.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
46 Hooker GW, Clemens KR, Quillin J, Vogel Postula KJ, Summerour P, Nagy R, Buchanan AH. Cancer Genetic Counseling and Testing in an Era of Rapid Change. J Genet Couns 2017;26:1244-53. [PMID: 28434142 DOI: 10.1007/s10897-017-0099-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
47 Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, Bremer RC, Rosenberg PS, Savage SA. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 2016;122:3673-81. [PMID: 27496084 DOI: 10.1002/cncr.30248] [Cited by in Crossref: 192] [Cited by in F6Publishing: 142] [Article Influence: 38.4] [Reference Citation Analysis]
48 Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, Petersen GM, Lerner-Ellis J, Holter S, Gallinger S. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 2015;148:556-64. [PMID: 25479140 DOI: 10.1053/j.gastro.2014.11.042] [Cited by in Crossref: 177] [Cited by in F6Publishing: 148] [Article Influence: 25.3] [Reference Citation Analysis]
49 Fecteau H, Vogel KJ, Hanson K, Morrill-Cornelius S. The evolution of cancer risk assessment in the era of next generation sequencing. J Genet Couns 2014;23:633-9. [PMID: 24756768 DOI: 10.1007/s10897-014-9714-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 6.9] [Reference Citation Analysis]
50 Cheon JY, Mozersky J, Cook-Deegan R. Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to come? Genome Med 2014;6:121. [PMID: 25593598 DOI: 10.1186/s13073-014-0121-3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 35] [Article Influence: 8.1] [Reference Citation Analysis]
51 Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw 2017;15:219-28. [PMID: 28188191 DOI: 10.6004/jnccn.2017.0022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
52 Mets S, Tryon R, Veach PM, Zierhut HA. Genetic Counselors' Experiences Regarding Communication of Reproductive Risks with Autosomal Recessive Conditions found on Cancer Panels. J Genet Couns 2016;25:359-72. [PMID: 26454646 DOI: 10.1007/s10897-015-9892-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
53 Yadav S, Reeves A, Campian S, Paine A, Zakalik D. Outcomes of retesting BRCA negative patients using multigene panels. Fam Cancer 2017;16:319-28. [PMID: 27878467 DOI: 10.1007/s10689-016-9956-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
54 Brnich SE, Rivera-Muñoz EA, Berg JS. Quantifying the potential of functional evidence to reclassify variants of uncertain significance in the categorical and Bayesian interpretation frameworks. Hum Mutat 2018;39:1531-41. [PMID: 30095857 DOI: 10.1002/humu.23609] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
55 Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015;33:304-11. [PMID: 25452441 DOI: 10.1200/JCO.2014.57.1414] [Cited by in Crossref: 342] [Cited by in F6Publishing: 197] [Article Influence: 48.9] [Reference Citation Analysis]
56 Hartley T, Cavallone L, Sabbaghian N, Silva-Smith R, Hamel N, Aleynikova O, Smith E, Hastings V, Pinto P, Tischkowitz M, Tomiak E, Foulkes WD. Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada. Hered Cancer Clin Pract 2014;12:19. [PMID: 25225577 DOI: 10.1186/1897-4287-12-19] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
57 Cline MS, Liao RG, Parsons MT, Paten B, Alquaddoomi F, Antoniou A, Baxter S, Brody L, Cook-Deegan R, Coffin A, Couch FJ, Craft B, Currie R, Dlott CC, Dolman L, den Dunnen JT, Dyke SOM, Domchek SM, Easton D, Fischmann Z, Foulkes WD, Garber J, Goldgar D, Goldman MJ, Goodhand P, Harrison S, Haussler D, Kato K, Knoppers B, Markello C, Nussbaum R, Offit K, Plon SE, Rashbass J, Rehm HL, Robson M, Rubinstein WS, Stoppa-Lyonnet D, Tavtigian S, Thorogood A, Zhang C, Zimmermann M, Burn J, Chanock S, Rätsch G, Spurdle AB; BRCA Challenge Authors. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet 2018;14:e1007752. [PMID: 30586411 DOI: 10.1371/journal.pgen.1007752] [Cited by in Crossref: 80] [Cited by in F6Publishing: 55] [Article Influence: 26.7] [Reference Citation Analysis]
58 De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. Mol Oncol. 2014;8:150-158. [PMID: 24220311 DOI: 10.1016/j.molonc.2013.10.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
59 Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, McGuire V, Ladabaum U, Kobayashi Y, Lincoln SE. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014;32:2001-2009. [PMID: 24733792 DOI: 10.1200/jco.2013.53.6607] [Cited by in Crossref: 322] [Cited by in F6Publishing: 159] [Article Influence: 46.0] [Reference Citation Analysis]
60 Slavin TP, Niell-Swiller M, Solomon I, Nehoray B, Rybak C, Blazer KR, Weitzel JN. Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. Front Oncol 2015;5:208. [PMID: 26484312 DOI: 10.3389/fonc.2015.00208] [Cited by in Crossref: 15] [Cited by in F6Publishing: 48] [Article Influence: 2.5] [Reference Citation Analysis]
61 Fahrioğlu U. Problems of Unknown Significance: Counseling in the Era of Next Generation Sequencing. Balkan J Med Genet 2018;21:73-6. [PMID: 30425914 DOI: 10.2478/bjmg-2018-0003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
62 Patrick-Miller LJ, Egleston BL, Fetzer D, Forman A, Bealin L, Rybak C, Peterson C, Corbman M, Albarracin J, Stevens E, Daly MB, Bradbury AR. Development of a communication protocol for telephone disclosure of genetic test results for cancer predisposition. JMIR Res Protoc 2014;3:e49. [PMID: 25355401 DOI: 10.2196/resprot.3337] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
63 Price KS, Svenson A, King E, Ready K, Lazarin GA. Inherited Cancer in the Age of Next-Generation Sequencing. Biol Res Nurs 2018;20:192-204. [PMID: 29325452 DOI: 10.1177/1099800417750746] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
64 Fostira F, Kostantopoulou I, Apostolou P, Papamentzelopoulou MS, Papadimitriou C, Faliakou E, Christodoulou C, Boukovinas I, Razis E, Tryfonopoulos D, Barbounis V, Vagena A, Vlachos IS, Kalfakakou D, Fountzilas G, Yannoukakos D. One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene. J Med Genet 2020;57:53-61. [PMID: 31300551 DOI: 10.1136/jmedgenet-2019-106189] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
65 Giri VN, Beebe-Dimmer JL. Familial prostate cancer. Semin Oncol 2016;43:560-5. [PMID: 27899188 DOI: 10.1053/j.seminoncol.2016.08.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 6.4] [Reference Citation Analysis]
66 Kluska A, Balabas A, Paziewska A, Kulecka M, Nowakowska D, Mikula M, Ostrowski J. New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing. BMC Med Genomics 2015;8:19. [PMID: 25948282 DOI: 10.1186/s12920-015-0092-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
67 Cragun D, Kinney AY, Pal T. Care delivery considerations for widespread and equitable implementation of inherited cancer predisposition testing. Expert Rev Mol Diagn 2017;17:57-70. [PMID: 27910721 DOI: 10.1080/14737159.2017.1267567] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
68 Yurgelun MB, Allen B, Kaldate RR, Bowles KR, Judkins T, Kaushik P, Roa BB, Wenstrup RJ, Hartman AR, Syngal S. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Gastroenterology 2015;149:604-13.e20. [PMID: 25980754 DOI: 10.1053/j.gastro.2015.05.006] [Cited by in Crossref: 147] [Cited by in F6Publishing: 113] [Article Influence: 24.5] [Reference Citation Analysis]
69 Maxwell KN, Wubbenhorst B, D'Andrea K, Garman B, Long JM, Powers J, Rathbun K, Stopfer JE, Zhu J, Bradbury AR, Simon MS, DeMichele A, Domchek SM, Nathanson KL. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genet Med 2015;17:630-8. [PMID: 25503501 DOI: 10.1038/gim.2014.176] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 12.3] [Reference Citation Analysis]
70 Brandão A, Paulo P, Teixeira MR. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. Int J Mol Sci 2020;21:E5036. [PMID: 32708810 DOI: 10.3390/ijms21145036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
71 Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Deapen D, Morrow M, Jagsi R, Katz SJ. Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer. JAMA Oncol 2020;6:e196400. [PMID: 32027353 DOI: 10.1001/jamaoncol.2019.6400] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
72 Mucaki EJ, Caminsky NG, Perri AM, Lu R, Laederach A, Halvorsen M, Knoll JH, Rogan PK. A unified analytic framework for prioritization of non-coding variants of uncertain significance in heritable breast and ovarian cancer. BMC Med Genomics 2016;9:19. [PMID: 27067391 DOI: 10.1186/s12920-016-0178-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
73 Wang A, Everett JN, Chun J, Cen C, Simeone DM, Schnabel F. Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer. Sci Rep 2021;11:12491. [PMID: 34127761 DOI: 10.1038/s41598-021-91971-0] [Reference Citation Analysis]
74 Scherr CL, Lindor NM, Malo TL, Couch FJ, Vadaparampil ST. Genetic counselors' practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing. Clin Genet 2015;88:523-9. [PMID: 25640009 DOI: 10.1111/cge.12563] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
75 Gomy I, Diz Mdel P. Hereditary cancer risk assessment: insights and perspectives for the Next-Generation Sequencing era. Genet Mol Biol 2016;39:184-8. [PMID: 27192130 DOI: 10.1590/1678-4685-GMB-2014-0346] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
76 Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Cancer 2020;126:549-58. [PMID: 31682005 DOI: 10.1002/cncr.32572] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
77 Park JS, Nam EJ, Park HS, Han JW, Lee JY, Kim J, Kim TI, Lee ST. Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls. Cancer Res Treat 2017;49:1012-21. [PMID: 28111427 DOI: 10.4143/crt.2016.433] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
78 Melas M, Subbiah S, Saadat S, Rajurkar S, McDonnell KJ. The Community Oncology and Academic Medical Center Alliance in the Age of Precision Medicine: Cancer Genetics and Genomics Considerations. J Clin Med 2020;9:E2125. [PMID: 32640668 DOI: 10.3390/jcm9072125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
79 Giri VN, Obeid E, Hegarty SE, Gross L, Bealin L, Hyatt C, Fang CY, Leader A. Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate 2018;78:879-88. [PMID: 29655297 DOI: 10.1002/pros.23535] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
80 Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol 2014;12:1059-68. [PMID: 23962553 DOI: 10.1016/j.cgh.2013.08.015] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
81 Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Oyama T, Mochizuki H, Omata M. Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer. Mol Genet Genomic Med 2015;3:459-66. [PMID: 26436112 DOI: 10.1002/mgg3.157] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 8.5] [Reference Citation Analysis]
82 Eliade M, Skrzypski J, Baurand A, Jacquot C, Bertolone G, Loustalot C, Coutant C, Guy F, Fumoleau P, Duffourd Y, Arnould L, Delignette A, Padéano MM, Lepage C, Raichon-Patru G, Boudrant A, Bône-Lépinoy MC, Villing AL, Charpin A, Peignaux K, Chevrier S, Vegran F, Ghiringhelli F, Boidot R, Sevenet N, Lizard S, Faivre L. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families? Oncotarget 2017;8:1957-71. [PMID: 27779110 DOI: 10.18632/oncotarget.12699] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
83 Cragun D, Radford C, Dolinsky JS, Caldwell M, Chao E, Pal T. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin Genet 2014;86:510-20. [PMID: 24506336 DOI: 10.1111/cge.12359] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 10.4] [Reference Citation Analysis]
84 Dutil J, Golubeva VA, Pacheco-Torres AL, Diaz-Zabala HJ, Matta JL, Monteiro AN. The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. Breast Cancer Res Treat 2015;154:441-53. [PMID: 26564481 DOI: 10.1007/s10549-015-3629-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 7.7] [Reference Citation Analysis]
85 Hamilton JG, Abdiwahab E, Edwards HM, Fang ML, Jdayani A, Breslau ES. Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda. J Gen Intern Med 2017;32:315-24. [PMID: 27995427 DOI: 10.1007/s11606-016-3943-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 32] [Article Influence: 9.8] [Reference Citation Analysis]
86 Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol 2015;26:1291-9. [PMID: 25605744 DOI: 10.1093/annonc/mdv022] [Cited by in Crossref: 134] [Cited by in F6Publishing: 92] [Article Influence: 22.3] [Reference Citation Analysis]